Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2019 3
2020 8
2021 7
2022 9
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023.
Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, Gniadecki R, Hodak E, Jonak C, Klemke CD, Knobler R, Morrris S, Nicolay JP, Ortiz-Romero PL, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer MH, Wehkamp U, Whittaker S, Willemze R, Trautinger F. Latzka J, et al. Eur J Cancer. 2023 Dec;195:113343. doi: 10.1016/j.ejca.2023.113343. Epub 2023 Sep 18. Eur J Cancer. 2023. PMID: 37890355 Free article. Review.
Major changes to the previous version include the incorporation of chlormethine, brentuximab vedotin, and mogamulizumab, recommendations on the use of pegylated interferon alpha (after withdrawal of recombinant unpegylated interferons), and the addition of paragraphs on su …
Major changes to the previous version include the incorporation of chlormethine, brentuximab vedotin, and mogamulizumab, recommendati …
Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies.
Mustafayev K, Torres H. Mustafayev K, et al. Clin Microbiol Infect. 2022 Oct;28(10):1321-1327. doi: 10.1016/j.cmi.2022.02.042. Epub 2022 Mar 10. Clin Microbiol Infect. 2022. PMID: 35283317 Free article. Review.
CONTENT: The risk of HBV or HCV reactivation is not well defined in cancer patients receiving immune checkpoint inhibitors (durvalumab, atezolizumab, nivolumab, pembrolizumab, ipilimumab, and tremelimumab); BTK inhibitors (ibrutinib and acalabrutinib); agents targeting CD22 (inot …
CONTENT: The risk of HBV or HCV reactivation is not well defined in cancer patients receiving immune checkpoint inhibitors (durvalumab, atez …
Mogamulizumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30272896 Free Books & Documents. Review.
No information is available on the passage of mogamulizumab into breastmilk. Because mogamulizumab is a large protein molecule with a molecular weight of 149,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the i …
No information is available on the passage of mogamulizumab into breastmilk. Because mogamulizumab is a large protein molecule …
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
Musiek ACM, Rieger KE, Bagot M, Choi JN, Fisher DC, Guitart J, Haun PL, Horwitz SM, Huen AO, Kwong BY, Lacouture ME, Noor SJ, Rook AH, Seminario-Vidal L, Vermeer MH, Kim YH. Musiek ACM, et al. Dermatol Ther (Heidelb). 2022 Jan;12(1):29-40. doi: 10.1007/s13555-021-00624-7. Epub 2021 Nov 23. Dermatol Ther (Heidelb). 2022. PMID: 34816383 Free PMC article. Review.
The CCR4-directed monoclonal antibody mogamulizumab has been shown to significantly improve progression-free survival and overall response rate compared with vorinostat in adults with relapsed/refractory mycosis fungoides (MF) and Sezary syndrome (SS). One of the most comm …
The CCR4-directed monoclonal antibody mogamulizumab has been shown to significantly improve progression-free survival and overall res …
Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma.
Pelcovits A, Ollila TA, Olszewski AJ. Pelcovits A, et al. Cancer Manag Res. 2023 Sep 6;15:989-998. doi: 10.2147/CMAR.S330908. eCollection 2023. Cancer Manag Res. 2023. PMID: 37700809 Free PMC article. Review.
Previous systemic therapies such as retinoids, histone deacetylase inhibitors, and chemotherapeutic agents come with significant toxicity and only short-term response. Newer agents such as mogamulizumab and brentuximab vedotin use a targeted immune-based approach leading t …
Previous systemic therapies such as retinoids, histone deacetylase inhibitors, and chemotherapeutic agents come with significant toxicity an …
Emerging drugs for the treatment of cutaneous T-cell lymphoma.
Cheng M, Zain J, Rosen ST, Querfeld C. Cheng M, et al. Expert Opin Emerg Drugs. 2022 Mar;27(1):45-54. doi: 10.1080/14728214.2022.2049233. Epub 2022 Mar 8. Expert Opin Emerg Drugs. 2022. PMID: 35235473 Free PMC article. Review.
AREAS COVERED: This review provides a discussion of recently approved biological and novel therapeutics that are actively developed for the management of the heterogeneous group of CTCL. EXPERT OPINION: Mogamulizumab and brentuximab vedotin have reached the market and are …
AREAS COVERED: This review provides a discussion of recently approved biological and novel therapeutics that are actively developed for the …
Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
Fernández-Guarino M, Ortiz P, Gallardo F, Llamas-Velasco M. Fernández-Guarino M, et al. Int J Mol Sci. 2024 Feb 12;25(4):2203. doi: 10.3390/ijms25042203. Int J Mol Sci. 2024. PMID: 38396877 Free PMC article. Review.
Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas (CTCL). ...
Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cu …
Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas.
Sonego B, Ibatici A, Rivoli G, Angelucci E, Sola S, Massone C. Sonego B, et al. Cells. 2023 Nov 20;12(22):2656. doi: 10.3390/cells12222656. Cells. 2023. PMID: 37998391 Free PMC article. Review.
In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mo …
In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-C …
Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review.
Nakahata S, Enriquez-Vera D, Jahan MI, Sugata K, Satou Y. Nakahata S, et al. Biomolecules. 2023 Oct 19;13(10):1543. doi: 10.3390/biom13101543. Biomolecules. 2023. PMID: 37892225 Free PMC article. Review.
Additionally, the activity of the anti-CC chemokine receptor 4 antibody, mogamulizumab, depends on immune function, including antibody-dependent cytotoxicity. ...
Additionally, the activity of the anti-CC chemokine receptor 4 antibody, mogamulizumab, depends on immune function, including antibod …
Mogamulizumab for Previously Treated Mycosis Fungoides and Sezary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE, Witlox W, Wolff R, Chalker A, Hiligsmann M, Wijnen B, Ahmadu C, Ryder S, Armstrong N, Duffy S, Syndikus I, Kleijnen J, Joore MA. Grimm SE, et al. Pharmacoeconomics. 2022 May;40(5):509-518. doi: 10.1007/s40273-021-01098-3. Epub 2021 Oct 19. Pharmacoeconomics. 2022. PMID: 34664200 Free PMC article. Review.
In response to the Appraisal Consultation Document, the company provided an unanchored matched adjusted indirect comparison (MAIC) of mogamulizumab with UK standard care by analysing Hospital Episode Statistics (HES) data. ...NICE did not recommend mogamulizumab for …
In response to the Appraisal Consultation Document, the company provided an unanchored matched adjusted indirect comparison (MAIC) of mog …
34 results